Generalized Anxiety Disorder
📧 Sign up to get email alerts when something new happens for Generalized Anxiety Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2014-12-17FDA Approved: EFFEXOR XR — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Effexor XR (venlafaxine hydrochloride) by Viatris Specialty LLC. The action is to modify labelin…
-
FDA approval · 2014-12-13FDA Approved: ESCITALOPRAM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for escitalopram (ESCITSLOPRAM), a generic antidepressant, bringing a generic v…
-
FDA approval · 2014-12-10FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for Escitalopram Oxalate from Amneal Pharmaceuticals LLC, enabling a generic version of escitalo…
-
CLINICAL_TRIALS trial_result · 2014-12-10Clinical Trial Update: A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder [Phase 3]
A phase 3 open-label pilot trial evaluating memantine as augmentation therapy for generalized anxiety disorder and social anxiety disorder, …
-
FDA approval · 2014-12-01FDA Approved: PAROXETINE — Supplemental Application (Padagis US LLC)
FDA approved a supplemental application for paroxetine submitted by Padagis US LLC, adding or updating labeling under the existing NDA.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2014-11-26FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for PAROXETINE (paroxetine hydrochloride) from Zydus Lifesciences Limited, enabling the marketing of…
-
FDA approval · 2014-11-17FDA Approved: VENLAFAXINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approval of a supplemental application for Venlafaxine from Sun Pharmaceutical Industries, confirming regulatory action on this generic …
-
FDA approval · 2014-11-04FDA Approved: ESCITALOPRAM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for escitalopram oxalate (escitalopram) from Sun Pharmaceutical Industries, Inc., approving changes …
-
FDA approval · 2014-10-31FDA Approved: ALPRAZOLAM — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for Alprazolam submitted by Sandoz Inc, related to a generic version of the drug.
-
FDA approval · 2014-10-31FDA Approved: PAROXETINE — Original Application (Solco Healthcare US, LLC)
FDA approved Solco Healthcare US, LLC's original ANDA for paroxetine hydrochloride hemihydrate (paroxetine), making a generic version of the…
-
FDA approval · 2014-10-21FDA Approved: EFFEXOR XR — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Effexor XR (venlafaxine extended-release) submitted by Viatris Specialty LLC.
-
CLINICAL_TRIALS trial_result · 2014-10-03Clinical Trial Update: Experimental Medication For the Treatment of Generalized Anxiety Disorder [Phase 3]
A Phase 3 clinical trial evaluating an experimental medication for generalized anxiety disorder has completed with results posted in 2014.
-
FDA approval · 2014-09-26FDA Approved: DULOXETINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for duloxetine from Zydus Lifesciences Limited under an ANDA. The approval involves changes to the a…
-
CLINICAL_TRIALS trial_result · 2014-09-25Clinical Trial Update: A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients [Phase 4]
Phase 4 clinical trial evaluating a collaborative care program to improve treatment of depression and anxiety disorders in patients with hea…
-
FDA approval · 2014-09-19FDA Approved: VENLAFAXINE — Supplemental Application (Alembic Pharmaceuticals Inc.)
FDA approved a supplemental application for venlafaxine by Alembic Pharmaceuticals, enabling a generic venlafaxine product through an ANDA s…
-
FDA approval · 2014-09-15FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for escitalopram oxalate from Rising Pharma Holdings, Inc., enabling the marketing of a generic …
-
CLINICAL_TRIALS trial_result · 2014-09-05Clinical Trial Update: Locating Regions of Interest in Generalized Anxiety Disorder Using Function Magnetic Resonance Imaging (fMRI)
This completed clinical trial investigated locating regions of interest in generalized anxiety disorder using functional MRI.
-
CLINICAL_TRIALS trial_result · 2014-09-03Clinical Trial Update: Efficacy Study of Abdominal Massage Therapy to Treat Generalized Anxiety Disorder of Deficiency of Both Heart and Spleen Type [NA]
This clinical trial update covers an efficacy study of abdominal massage therapy for Generalized Anxiety Disorder (deficiency of heart and s…
-
CLINICAL_TRIALS trial_result · 2014-08-28Clinical Trial Update: Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector [Phase 1]
Phase 1 trial results for a cognitive-behavioral therapy program addressing generalized anxiety disorder in Latino patients in general medic…
-
FDA approval · 2014-08-25FDA Approved: BUSPIRONE HYDROCHLORIDE — Original Application (Strides Pharma Inc.)
FDA approved the original application for buspirone hydrochloride (generic) from Strides Pharma Inc., signaling the availability of a generi…
-
CLINICAL_TRIALS trial_result · 2014-08-21Clinical Trial Update: Quetiapine in Co-Morbid Depressive and Anxiety Disorders [NA]
A completed clinical trial evaluating quetiapine for co-morbid depressive and anxiety disorders, including major depressive disorder, dysthy…
-
FDA approval · 2014-08-08FDA Approved: ALPRAZOLAM — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for Alprazolam from Mylan Pharmaceuticals Inc., indicating regulatory approval for a supplementa…
-
CLINICAL_TRIALS research · 2014-07-21Clinical Trial Update: Attention Retraining for Anxiety Disorder Patients Resistent to Antidepressants [NA]
This clinical trial update describes a study on attention retraining for anxiety disorder patients who have not responded to antidepressants…
-
FDA label_change · 2014-07-18FDA Approved: VENLAFAXINE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for Venlafaxine from BluePoint Laboratories. The update concerns this generic product's regulatory s…
-
CLINICAL_TRIALS research · 2014-07-18Clinical Trial Update: Transdisciplinary Studies of CBT for Anxiety in Youth: Child Anxiety Treatment Study [NA]
A completed clinical trial evaluating cognitive-behavioral therapy for anxiety in youth, covering generalized anxiety disorder, separation a…